100,000 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Purchased by Octagon Capital Advisors LP

Octagon Capital Advisors LP acquired a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 100,000 shares of the biotechnology company’s stock, valued at approximately $105,000. Octagon Capital Advisors LP owned approximately 0.14% of Aclaris Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ACRS. Barclays PLC boosted its stake in Aclaris Therapeutics by 174.2% in the 3rd quarter. Barclays PLC now owns 234,150 shares of the biotechnology company’s stock valued at $1,603,000 after buying an additional 148,761 shares in the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Aclaris Therapeutics by 14.0% during the third quarter. Lord Abbett & CO. LLC now owns 453,954 shares of the biotechnology company’s stock valued at $3,110,000 after acquiring an additional 55,602 shares during the period. Algert Global LLC acquired a new stake in shares of Aclaris Therapeutics in the 3rd quarter valued at $309,000. Trexquant Investment LP bought a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth about $876,000. Finally, Corton Capital Inc. acquired a new stake in shares of Aclaris Therapeutics during the 3rd quarter worth about $102,000. 98.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.25.

Aclaris Therapeutics Stock Down 0.8 %

Shares of NASDAQ ACRS opened at $1.18 on Friday. Aclaris Therapeutics, Inc. has a 12-month low of $0.59 and a 12-month high of $11.12. The firm’s 50-day simple moving average is $1.17 and its 200 day simple moving average is $1.15. The company has a market cap of $84.09 million, a price-to-earnings ratio of -1.08 and a beta of 0.06.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. On average, equities analysts expect that Aclaris Therapeutics, Inc. will post -0.81 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Braden Michael Leonard bought 528,621 shares of the stock in a transaction dated Thursday, June 13th. The stock was bought at an average cost of $1.15 per share, with a total value of $607,914.15. Following the purchase, the insider now owns 11,007,134 shares of the company’s stock, valued at $12,658,204.10. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 6.40% of the stock is currently owned by corporate insiders.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.